Tema Etfs LLC Boosts Stake in Gilead Sciences, Inc. $GILD

Key Points

• Tema Etfs LLC increased its stake in Gilead Sciences, Inc. by 25.2% in the first quarter, now holding 38,622 shares valued at approximately $4.3 million.
• Gilead Sciences reported earnings of $2.01 per share for the last quarter, exceeding analyst expectations, with revenue of $7.08 billion.
• The company's quarterly dividend of $0.79 will be paid on September 29th, representing an annual yield of 2.8%.

Tema Etfs LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 25.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,622 shares of the biopharmaceutical company's stock after purchasing an additional 7,776 shares during the period. Gilead Sciences comprises approximately 1.3% of Tema Etfs LLC's investment portfolio, making the stock its 19th biggest position. Tema Etfs LLC's holdings in Gilead Sciences were worth $4,328,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Nissay Asset Management Corp Japan ADV increased its holdings in Gilead Sciences by 5.2% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after purchasing an additional 14,009 shares during the period. Golden State Wealth Management LLC boosted its position in Gilead Sciences by 14.5% during the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock valued at $97,000 after acquiring an additional 109 shares during the last quarter. Mufg Securities Americas Inc. bought a new stake in Gilead Sciences during the fourth quarter valued at $1,699,000. ASR Vermogensbeheer N.V. bought a new stake in Gilead Sciences during the first quarter valued at $11,688,000. Finally, Wealth Enhancement Advisory Services LLC boosted its position in Gilead Sciences by 4.7% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 292,966 shares of the biopharmaceutical company's stock valued at $32,827,000 after acquiring an additional 13,194 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $113.94, for a total value of $1,139,400.00. Following the transaction, the chief executive officer owned 605,725 shares of the company's stock, valued at approximately $69,016,306.50. This trade represents a 1.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock worth $9,371,330 in the last quarter. 0.27% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have commented on GILD. Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their price target for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research report on Friday, July 25th. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target on the stock in a research report on Tuesday, August 19th. Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research report on Friday, August 8th. Finally, UBS Group upped their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Stock Up 0.4%

Shares of GILD stock traded up $0.41 on Monday, reaching $112.97. 4,629,720 shares of the company were exchanged, compared to its average volume of 6,308,101. The company has a market cap of $140.17 billion, a price-to-earnings ratio of 22.50, a PEG ratio of 0.70 and a beta of 0.36. The company has a 50-day moving average of $113.01 and a 200-day moving average of $109.66. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a one year low of $77.74 and a one year high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business's revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be given a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.